OBJECTIVE: Myeloablative total body irradiation (TBI) in the setting of autologous transplantation of genetically modified hematopoietic stem cells (HSC) is associated with substantial toxicity. Nonmyeloablative doses of TBI are less toxic, but result in low-level engraftment of genetically modified HSCs. As an alternative to TBI, escalating doses of parenteral busulfan were tested for their hematologic toxicity, their ability to promote donor leukocyte engraftment, and the time window for such engraftment. MATERIALS AND METHODS: Hematologic toxicity of busulfan was assessed in C57BL6 mice after single nonmyeloablative doses of intraperitoneal busulfan ranging from 1 to 40 mg/kg by serial complete blood counts monitored up to 40 days. The level of donor engraftment attainable after nonmyeloablative busulfan was determined by infusion of 20 million congenic murine bone marrow nucleated cells (BMNC) following 5 to 40 mg/kg of busulfan. To determine the effects of delayed HSC infusions, BMNCs were infused 1, 10, 15, and 20 days after a single dose of 10 mg/kg of busulfan. RESULTS: Busulfan doses from 1 to 40 mg/kg produced hematologic toxicity that was most pronounced in the 2nd to 3rd week. In transplantation experiments, dose-dependent donor leukocyte engraftment was attained with levels >70% after only 20 mg/kg of busulfan. Similar levels of engraftment were achieved even when infusion of BMNCs was delayed up to 20 days after busulfan injection. CONCLUSION: Nonmyeloablative parenteral busulfan produced transient myelosuppressive effects, clinically relevant levels of engraftment, and an extended time window for HSC infusion in murine hosts.
OBJECTIVE: Myeloablative total body irradiation (TBI) in the setting of autologous transplantation of genetically modified hematopoietic stem cells (HSC) is associated with substantial toxicity. Nonmyeloablative doses of TBI are less toxic, but result in low-level engraftment of genetically modified HSCs. As an alternative to TBI, escalating doses of parenteral busulfan were tested for their hematologic toxicity, their ability to promote donor leukocyte engraftment, and the time window for such engraftment. MATERIALS AND METHODS: Hematologic toxicity of busulfan was assessed in C57BL6 mice after single nonmyeloablative doses of intraperitoneal busulfan ranging from 1 to 40 mg/kg by serial complete blood counts monitored up to 40 days. The level of donor engraftment attainable after nonmyeloablative busulfan was determined by infusion of 20 million congenic murine bone marrow nucleated cells (BMNC) following 5 to 40 mg/kg of busulfan. To determine the effects of delayed HSC infusions, BMNCs were infused 1, 10, 15, and 20 days after a single dose of 10 mg/kg of busulfan. RESULTS:Busulfan doses from 1 to 40 mg/kg produced hematologic toxicity that was most pronounced in the 2nd to 3rd week. In transplantation experiments, dose-dependent donor leukocyte engraftment was attained with levels >70% after only 20 mg/kg of busulfan. Similar levels of engraftment were achieved even when infusion of BMNCs was delayed up to 20 days after busulfan injection. CONCLUSION: Nonmyeloablative parenteral busulfan produced transient myelosuppressive effects, clinically relevant levels of engraftment, and an extended time window for HSC infusion in murine hosts.
Authors: Timothy Madden; Marcos de Lima; Neil Thapar; John Nguyen; Soonja Roberson; Daniel Couriel; Betty Pierre; Elizabeth J Shpall; Roy B Jones; Richard E Champlin; Borje S Andersson Journal: Biol Blood Marrow Transplant Date: 2007-01 Impact factor: 5.742
Authors: Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez Journal: Nat Med Date: 2006-04-02 Impact factor: 53.440
Authors: Gennadiy Kovtunovych; Manik C Ghosh; Wade Ollivierre; R Patrick Weitzel; Michael A Eckhaus; John F Tisdale; Akihiro Yachie; Tracey A Rouault Journal: Blood Date: 2014-06-24 Impact factor: 22.113
Authors: Selami Demirci; Jing Zeng; Yuxuan Wu; Naoya Uchida; Anne H Shen; Danilo Pellin; Jackson Gamer; Morgan Yapundich; Claire Drysdale; Jasmine Bonanno; Aylin C Bonifacino; Allen E Krouse; Nathaniel S Linde; Theresa Engels; Robert E Donahue; Juan J Haro-Mora; Alexis Leonard; Tina Nassehi; Kevin Luk; Shaina N Porter; Cicera R Lazzarotto; Shengdar Q Tsai; Mitchell J Weiss; Shondra M Pruett-Miller; Scot A Wolfe; Daniel E Bauer; John F Tisdale Journal: J Clin Invest Date: 2020-12-01 Impact factor: 14.808
Authors: Jianjun Xie; Andre Larochelle; Irina Maric; Marion Faulhaber; Robert E Donahue; Cynthia E Dunbar Journal: Hum Gene Ther Date: 2010-06 Impact factor: 5.695
Authors: Coral-Ann B Lewis; John Manning; Christine Barr; Kyle Peake; R Keith Humphries; Fabio Rossi; Charles Krieger Journal: PLoS One Date: 2013-04-08 Impact factor: 3.240